Nilsan Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 23-10-2024
- Paid Up Capital ₹ 2.00 M
as on 23-10-2024
- Company Age 28 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.42 Cr
as on 23-10-2024
- Revenue -10.56%
(FY 2023)
- Profit -5.37%
(FY 2023)
- Ebitda -147.08%
(FY 2023)
- Net Worth 32.26%
(FY 2023)
- Total Assets 23.65%
(FY 2023)
About Nilsan Pharmaceuticals
The Corporate was formerly known as Nelcom Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹5.42 Cr.
Sandeep Garg and Kavita Garg serve as directors at the Company.
- CIN/LLPIN
U74210DL1996PTC080481
- Company No.
080481
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jul 1996
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Nilsan Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandeep Garg  | Director | 18-Jul-1996 | Current |
| Kavita Garg | Director | 01-Oct-2013 | Current |
Financial Performance of Nilsan Pharmaceuticals.
Nilsan Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 10.56% decrease. The company also saw a slight decrease in profitability, with a 5.37% decrease in profit. The company's net worth Soared by an impressive increase of 32.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nilsan Pharmaceuticals?
In 2023, Nilsan Pharmaceuticals had a promoter holding of 49.56% and a public holding of 50.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Aug 2024 | ₹4.47 Cr | Open |
Others Creation Date: 28 Jun 2018 | ₹9.00 M | Open |
Punjab & Sind Bank Creation Date: 20 Jul 1998 | ₹0.50 M | Open |
How Many Employees Work at Nilsan Pharmaceuticals?
Unlock and access historical data on people associated with Nilsan Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nilsan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nilsan Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
